The National Institute on Aging, part of the National Institutes of Health, grants RevBio, Inc. a Phase II Small Business Innovation Research (SBIR) of $2 million over two years. This funding will allow the company to pursue the treatment of wrist fractures with its patented bone adhesive technology known as Tetranite. As the bone adhesive is injectable by creating a small incision in a patient’s skin to deliver the material, making it a more minimally invasive treatment option than open surgery.
Dr. Jesse Jupiter, Hansjorg Wyss AO Professor of Orthopaedic Surgery, Harvard Medical School and an internationally known hand and upper extremity specialist who practices, Massachusetts General Hospital, said: “Many complications can occur in the healing of these kinds of compression fractures. Based on what I’ve seen, the ability to treat this common fracture safely by percutaneous means could significantly improve the way these fractures are treated.”
Rick Gennett, Past President of the Trauma Division, Synthes (now part of Johnson & Johnson), said: “This would be a significant step forward for surgeons and their patients.”
Brian Hess, CEO, RevBio, said: “This opportunity really showcases the reason we invented this product—to provide surgeons with a first-ever regenerative bone adhesive. This is the first of many indications we intend to launch to revolutionize how bone fractures are treated.”